DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquı́n Mateo, Johann S. de Bono, Emma Hall et al.|New England Journal of Medicine|2015Cited by 2.2k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Núria Porta et al.|The Lancet Oncology|2019Cited by 643
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Johann S. de Bono, Joaquı́n Mateo et al.|Cancer Discovery|2017Cited by 422
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by ApheresisMaryou Lambros, Johann S. de Bono, George Seed et al.|Clinical Cancer Research|2018Cited by 110
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate CancerAdam Sharp, Johann S. de Bono, Jon Welti et al.|European Urology|2019Cited by 83